Brodalumab, a Human Anti-Interleukin-17 Receptor A Monoclonal Antibody, Shows Low Immunogenicity in Patients with Moderate-to-Severe Psoriasis. J of Skin. 2018;2(S1):S1. doi:10.25251/skin.2.supp.1